Loading
Italian melanoma oncologist who co-led CheckMate 238, CheckMate 067 and the COLUMBUS BRAF/MEK trial.
Paolo Ascierto has been a lead investigator on most of the pivotal melanoma trials of the past decade, including CheckMate 238 (adjuvant nivolumab), CheckMate 067, COLUMBUS (encorafenib plus binimetinib) and the CheckMate 915 and RELATIVITY programmes. He founded the Melanoma Bridge and Immunotherapy Bridge meetings and leads one of Europe's largest melanoma units in Naples.
| Title | Journal | Year |
|---|---|---|
| Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238): 4-year results | Lancet Oncology | 2020 |
| Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS) | Lancet Oncology | 2018 |
Shares CheckMate 067, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
Shares BRAF, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
Shares CheckMate 067, Ipilimumab, Nivolumab, PD-1 and the tags melanoma, immunotherapy.
Shares BRAF V600-mutant melanoma, Melanoma and the tags melanoma, immunotherapy.
Shares BRAF V600-mutant melanoma, BRAF, Ipilimumab, Nivolumab and the tag melanoma.
Shares BRAF V600-mutant melanoma, Melanoma and the tags melanoma, immunotherapy.
Shares COLUMBUS, Encorafenib, BRAF, Melanoma and the tag melanoma.
Shares coBRIM, CheckMate 238, CheckMate 067, Ipilimumab.